

UNCLASSIFIED

AD NUMBER
ADB262612
NEW LIMITATION CHANGE
TO Approved for public release, distribution unlimited
FROM Distribution authorized to U.S. Gov't. agencies only; Proprietary Info.; Dec 99. Other requests shall be referred to U.S. Army Medical Research and Materiel Command, 504 Scott St., Fort Detrick, MD 21702-5012.
AUTHORITY
USAMRMC ltr, 26 Nov 2002

THIS PAGE IS UNCLASSIFIED

AD _____

Award Number: DAMD17-98-1-8266

TITLE: Search for Physiological Substrates of Protein Tyrosine
Phosphatase Epsilon in Mammary Tumor Cell Lines

PRINCIPAL INVESTIGATOR: Ari Elson, Ph.D.

CONTRACTING ORGANIZATION: The Weizmann Institute of Science
76100 Rehovot, Israel

REPORT DATE: December 1999

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Distribution authorized to U.S. Government agencies only (proprietary information, Dec 99). Other requests for this document shall be referred to U.S. Army Medical Research and Materiel Command, 504 Scott Street, Fort Detrick, Maryland 21702-5012.

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

DTIC QUALITY INSPECTED 4
20010124 072

NOTICE

USING GOVERNMENT DRAWINGS, SPECIFICATIONS, OR OTHER DATA INCLUDED IN THIS DOCUMENT FOR ANY PURPOSE OTHER THAN GOVERNMENT PROCUREMENT DOES NOT IN ANY WAY OBLIGATE THE U.S. GOVERNMENT. THE FACT THAT THE GOVERNMENT FORMULATED OR SUPPLIED THE DRAWINGS, SPECIFICATIONS, OR OTHER DATA DOES NOT LICENSE THE HOLDER OR ANY OTHER PERSON OR CORPORATION; OR CONVEY ANY RIGHTS OR PERMISSION TO MANUFACTURE, USE, OR SELL ANY PATENTED INVENTION THAT MAY RELATE TO THEM.


LIMITED RIGHTS LEGEND

Award Number: DAMD17-98-1-8266

Organization: The Weizmann Institute of Science

Those portions of the technical data contained in this report marked as limited rights data shall not, without the written permission of the above contractor, be (a) released or disclosed outside the government, (b) used by the Government for manufacture or, in the case of computer software documentation, for preparing the same or similar computer software, or (c) used by a party other than the Government, except that the Government may release or disclose technical data to persons outside the Government, or permit the use of technical data by such persons, if (i) such release, disclosure, or use is necessary for emergency repair or overhaul or (ii) is a release or disclosure of technical data (other than detailed manufacturing or process data) to, or use of such data by, a foreign government that is in the interest of the Government and is required for evaluational or informational purposes, provided in either case that such release, disclosure or use is made subject to a prohibition that the person to whom the data is released or disclosed may not further use, release or disclose such data, and the contractor or subcontractor or subcontractor asserting the restriction is notified of such release, disclosure or use. This legend, together with the indications of the portions of this data which are subject to such limitations, shall be included on any reproduction hereof which includes any part of the portions subject to such limitations.

THIS TECHNICAL REPORT HAS BEEN REVIEWED AND IS APPROVED FOR PUBLICATION.



01/04/01

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE December 1999		3. REPORT TYPE AND DATES COVERED Annual (1 Dec 98 - 30 Nov 99)	
4. TITLE AND SUBTITLE Search for Physiological Substrates of Protein Tyrosine Phosphatase Epsilon in Mammary Tumor Cell Lines				5. FUNDING NUMBERS DAMD17-98-1-8266	
6. AUTHOR(S) Ari Elson, Ph.D.					
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) The Weizmann Institute of Science 76100 Rehovot, Israel E-MAIL: ari.elson@weizmann.ac.il				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSORING / MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES					
12a. DISTRIBUTION / AVAILABILITY STATEMENT Distribution authorized to U.S. Government agencies only (proprietary information, Dec 99). Other requests for this document shall be referred to U.S. Army Medical Research and Materiel Command, 504 Scott Street, Fort Detrick, Maryland 21702-5012.					12b. DISTRIBUTION CODE
13. ABSTRACT (Maximum 200 Words) In this annual report we describe construction of substrate-trapping mutants of protein tyrosine phosphatase epsilon (PTPε) and the first round of experiments aimed at identification of physiological substrates of PTPε. Mutant PTPε molecules fused to glutathione-S-transferase (GST) were constructed, as were vectors for expressing mutant PTPε molecules in eukaryotic cells. GST fusion proteins could not be isolated in the absence of degradation; eukaryotic expression vectors, however, allowed us to appropriately express mutant PTPε molecules in transfected cells. Use of these mutants enabled us to establish that alpha subunits of voltage-gated potassium (Kv) channels are physiological substrates of PTPε and can be trapped by substrate-trapping mutants of PTPε. Furthermore, work described here provided a much-needed opportunity for calibrating and perfecting technical procedures for trapping substrates with these mutants. This experience will be implemented in future searches for PTPε substrates, searches guided by "educated guesses" of the identities of possible substrates of PTPε, or performed as general screens of mammary tumor cell lines.					
14. SUBJECT TERMS Breast Cancer, tyrosine phosphatase, substrate				15. NUMBER OF PAGES 20	
				16. PRICE CODE	
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Limited		

FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the U.S. Army.

___ Where copyrighted material is quoted, permission has been obtained to use such material.

___ Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

AG. Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

AG. X In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and use of Laboratory Animals of the Institute of Laboratory Resources, national Research Council (NIH Publication No. 86-23, Revised 1985).

AG. X For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

AG. N/A In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

AG. N/A In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

AG. N/A In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.



PI - Signature

12-8-1999

Date

Table of Contents

SF 298	2
Foreword	3
Table of Contents	4
Introduction	5
Body of Report	6
Key Research Accomplishments	11
Reportable Outcomes	11
Conclusions	12
References	13
Appendices (Figures)	15

5. Introduction:

Our research focuses on providing molecular-level understanding the role of protein tyrosine phosphatase epsilon (PTP ϵ) in the genesis of breast cancer by identifying physiological substrates of the enzyme. We have previously demonstrated a link between PTP ϵ and genesis of mammary tumors in mice *in vivo*; the project supported by the USAMRMC is aimed at taking these findings one step further by defining what is one of the most basic items of information needed to understand the role an enzyme - the identities of its substrates. We aim to achieve this goal through use of novel substrate-trapping methodology, i.e., by use of PTP ϵ mutants which have lost most of their catalytic ability but are able to bind their phosphorylated substrates and remain bound to them during purification. The exact theoretical details of how to construct such mutants have been published in the scientific literature and are briefly summarized below; our aim is to apply this knowledge to PTP ϵ , and to identify substrates of the enzyme in the context of breast tumor cell lines. Specifically, we aim to construct and characterize the necessary mutant PTP ϵ molecules, to identify proteins which bind PTP ϵ substrate-traps or to verify that candidate substrates of PTP ϵ indeed bind substrate-trapping mutants of PTP ϵ , to verify that molecules which bind are indeed substrates of PTP ϵ , and to understand how dephosphorylation by PTP ϵ affects their function. In this first annual report we describe generation of the appropriate mutants and preliminary studies we have performed with them.

6. Body of report:

Brief overview of substrate-trapping technology:

Substrate-trapping mutants of PTPases are PTPase molecules in which specific mutations have been introduced such that the resulting molecules are either almost or entirely devoid of catalytic activity, but retain the ability to bind their phosphorylated substrates and to remain bound to them (Sun et al., 1993; Flint et al., 1997). Binding is typically strong enough to withstand the rigors of immune-precipitation or related procedures, making substrate-trapping mutants "affinity reagents" of sorts for identifying physiological substrates of the phosphatase at hand. Two generic substrate-trapping mutations in PTPases have been described - mutation of the cysteine residue located at the core of the catalytic domain to a serine residue (C-to-S mutation), or mutation of a nearby aspartic acid residue to an alanine (D-to-A) (Flint et al., 1997; Sun et al., 1993). Both residues are strictly conserved in all known PTPases, making this approach systematically applicable to the entire PTPase family. We have undertaken to construct D-to-A mutants of PTP ϵ , either as glutathione-S-transferase (GST) fusion proteins or as proteins which can be exogenously expressed in cells. Both types of reagents are useful to similar extents in such studies, although the technical details of their production and utilization differ somewhat.

Studies planned for the period covered by this report:

During the period covered by this report, which constitutes the first year of the funding period, we undertook to develop substrate-trapping mutants of PTP ϵ and to perform an initial series of experiments with them aimed at identifying molecules trapped by these mutants. The Research Proposal described both GST-(D-to-A)-PTP ϵ fusion proteins as well as D-to-A PTP ϵ cDNAs which can be exogenously expressed in transfected cells, and identified GST fusion proteins as our first tool of choice. We planned to use GST-PTP ϵ proteins in "pull-down" experiments, i.e., addition of GST-PTP ϵ to lysates of cells or tissues, followed by re-isolation of the GST fusion proteins and any molecules which bound them. An alternative approach for the same basic goal was construction of eukaryotic vector plasmids for expression of mutant, substrate-trapping PTP ϵ molecules in cultured cells. Substrate-trapping mutants of PTP ϵ were to be immune-precipitated together with molecules which bound them.

Studies performed during the period covered by the report:

A. Construction of GST-PTP ϵ fusion molecules:

Bacterial expression vectors in which the entire cytoplasmic domain of tm-PTP ϵ , containing both catalytic domains (D1&D2), or just the membrane-proximal (D1) catalytic domain of the enzyme were constructed in the pGEX2TK plasmid (Pharmacia). The required fragments of PTP ϵ were amplified from tm-PTP ϵ cDNA (clone 58, Elson and Leder, 1995a) by PCR, using the e5common oligomer (GGGGATCCAGGTTCCGGAAGCAGAGGA), together with either the AEF3.1 oligomer (TGAAGTCTTCCTCCAGCCCG, for the D1 construct) or the Y695/NHE oligomer (GGGCTAGCTCATTTGAAATTAGCATA, for the D1&D2 construct) (See Figure 1). D-to-A mutants, in which the aspartic acid of the D1 domain was mutated to an alanine, were created by site-directed mutagenesis (Kunkel, 1985). The relevant DNA

fragments were cloned into the BamHI/SmaI sites of pGEX2TK; the resulting plasmids were expressed in the BL-21 strain of *E. coli* bacteria.

GST-PTP ϵ fusion proteins were purified from crude bacterial lysates with the use of glutathione-agarose beads (Pharmacia). Expression of GST-PTP ϵ fusion proteins was verified by protein blotting of extracts of bacteria with anti-PTP ϵ antibodies, and by Coomassie blue staining of SDS-polyacrylamide gels through which the lysates or purified proteins had been electrophoresed (Figure 2). In general, protein blot analysis revealed that the GST fusion proteins indeed reacted with anti-PTP ϵ antibodies, indicating that the bacterial expression vectors drove expression of the correct protein. However, Coomassie blue analysis of the purity and of the size of the GST-fusion proteins indicated that full-length GST-PTP ϵ proteins were not being produced in an adequate manner. The protein preparations contained, in addition to full-length GST-PTP ϵ protein, shorter proteins which were likely products of specific cleavage and non-specific degradation (Figure 2). Problems of this nature are often associated with production of GST fusion proteins, especially long ones, as was the case here.

Difficulties of this nature may be overcome by optimizing growth conditions of the bacteria in which the GST fusion proteins are produced. We attempted to grow the GST fusion proteins in BL21 and BL26 bacteria, the *E. coli* strains recommended by the manufacturer (Pharmacia), as well as in other bacteria strains, such as DH5 and XL-1-Blue. We also attempted to limit protein degradation by slowing down the rate of bacterial growth. This was done by growing bacteria in relatively poor media, at temperatures lower than the standard 37 degrees, or by reducing shaking (and aeration) of the bacterial cultures. None of these attempts at optimizing production of GST-PTP ϵ proteins significantly improved the situation. We currently can produce GST-PTP ϵ fusion proteins which contain some full-length product together with significant amounts of degraded material. As our substrate-trapping reagents are key to the success of this project, we felt that we should attempt to produce better reagents for initial substrate-trapping, although we may use our GST-PTP ϵ proteins in the future for studies of a confirmatory nature.

B. Construction of D-to-A mutants of PTP ϵ in eukaryotic expression vectors.

Due to the difficulties encountered in production of GST-(D-to-A)PTP ϵ , we turned to constructing eukaryotic vectors for expressing D-to-A PTP ϵ in eukaryotic cells. The original Research Proposal made provisions for following this course of action should the need arise.

The desired D-to-A mutations were inserted into the cDNAs of the two major forms of PTP ϵ - transmembranal PTP ϵ (tmPTP ϵ , Elson and Leder, 1995a) and cytoplasmic PTP ϵ (Elson and Leder, 1995b). Mutations were inserted using the Kunkel technique for site-directed mutagenesis (Kunkel, 1985); presence of the desired mutations and absence of other sequence changes were verified by sequencing. Both mutant cDNAs (D302A tm-PTP ϵ and D245A cyt-PTP ϵ) were cloned into the pCDNA3 expression vector, and their expression in 293 and COS cells was verified by transient expression and protein blotting with anti-PTP ϵ serum (Elson and Leder, 1995a) (Figure 3).

D-to-A mutants of tyrosine phosphatases are known to be virtually inactive (Flint et al., 1997). In order to determine whether this was the case with our series of D-to-A mutants of PTP ϵ , we compared total tyrosine-phosphatase activity in cells into

PAGE CONTAINS UNPUBLISHED DATA WHICH SHOULD BE PROTECTED

which we had transfected wild-type PTP ϵ or D-to-A mutants of PTP ϵ (Figure 4). Briefly, experiments were performed as follows:

- * 293 cells were transiently transfected by the calcium-phosphate technique, with the relevant PTP ϵ cDNAs in the pCDNA3 backbone.
- * Following lysis in an NP-40-based lysis buffer, protein content of the lysates was measured. Equal amounts of protein were incubated together with paranitrophenyl-phosphate (PNPP), a substrate for phosphatase activity. Dephosphorylation of PNPP yields a product which absorbs light at 405nm; phosphatase activity was then followed as the change in OD405 as a function of time elapsed (up to 120 minutes).
- * PNPP can be the substrate also of non tyrosine-specific phosphatases. To correct for this, each experiment was repeated also in the presence of 1mM sodium pervanadate, a powerful, irreversible, and specific inhibitor of tyrosine phosphatases (Huyer et al., 1997; Flint et al., 1997). The rate of PNPP dephosphorylation in the presence of pervanadate was taken to represent activity of non tyrosine-specific phosphatases and was subtracted from the total activity measured without pervanadate.
- * Samples containing equal amounts of protein from all cell lysates were examined by protein blotting with anti-PTP ϵ antibodies to verify equal expression levels of the transfected proteins and to ensure that differences in PTPase activity were not due simply to variable expression levels of PTP ϵ in the transfected cells.

As seen in Figure 4, all D-to-A mutants of tm- or of cyt-PTP ϵ were entirely inactive, in agreement with our expectations. Presence of a FLAG tag at the extreme carboxy-terminus of PTP ϵ molecules did not affect catalytic activity. Similar results were later obtained in assaying the ability of wild-type or of mutant PTP ϵ to inhibit activity of voltage-gated potassium channel activity in *Xenopus* oocytes (see below).

C. Use of D-to-A mutants of PTP ϵ :

Identification of voltage-gated potassium channels as physiological substrates of PTP ϵ . In parallel to the research effort described above, we had been characterizing the phenotype of PTP ϵ -deficient, knockout mice we had produced and had come across a defect in myelination of axons in their peripheral nerve system. We had evidence to suggest that this defect was due to aberrant phosphorylation of voltage-gated potassium (Kv) channels in Schwann cells of these mice, and wished to use the substrate-trapping system described above to determine whether Kv channels were in fact substrates of PTP ϵ . Although the studies which led to this point fall outside the scope of the current project, we felt that use of substrate-trapping mutants was nonetheless highly relevant to the goals of the study reported here. The Kv channel study provided us with an excellent opportunity to verify the functionality of the reagents we had constructed and of our operating procedures, using a defined candidate substrate of PTP ϵ , which preliminary evidence indicated was very likely to turn out to be a physiological substrate of PTP ϵ . Furthermore, Kv channels are quite widespread and are expressed in many organs and tissue types which are not conceived as being electrically excitable (Lewis and Cahalan, 1995), raising the possibility that Kv channels may be relevant substrates of PTP ϵ also in the context of breast cancer. In what follows we outline our studies in this direction, focusing in particular on the role of PTP ϵ substrate-trapping mutants.

Previous findings relating to Kv channels in PTP ϵ -deficient mice: In the process of characterizing PTP ϵ -deficient mice we performed an electron microscopy-based study of

PAGE CONTAINS UNPUBLISHED DATA WHICH SHOULD BE PROTECTED

the thickness of myelin sheaths surrounding axons in the sciatic nerves of these mice. The original rationale for performing this study was based on knowledge that myelination of peripheral nerves is dependent upon the well-being and functioning of Schwann cells, that Schwann cell proliferation and function is strongly influenced by the functioning of Kv channels expressed in them, and that Kv channels, in turn, can be regulated by Src- and Fyn-mediated tyrosine phosphorylation (Peretz et al., 1999). Several studies documenting functional connections between Src and Fyn, on the one hand, and PTP α , a PTPase extremely closely related to PTP ϵ , on the other hand, have been published (Zheng et al., 1992; Su et al., 1999; Ponniah et al., 1999). This suggested to us that perhaps PTP ϵ could be involved in regulation of Kv channel function in Schwann cells, and that this may be manifested in abnormal myelination of axons.

We first established that primary Schwann cells do in fact express PTP ϵ (Figure 5). We then examined the extent of myelination in PTP ϵ -deficient sciatic nerve axons and found it to be severely reduced compared to wild-type samples (Figure 6). Further studies revealed that alpha subunits of Kv channels in primary Schwann cells derived from PTP ϵ -deficient mice were hyperphosphorylated when compared to age-matched controls (Figure 7). Furthermore, patch-clamp measurements performed on primary Schwann cells revealed that Kv channel activity was markedly elevated in PTP ϵ -deficient cells (Figure 8). Together, these results indicated that lack of cyt-PTP ϵ caused hyperphosphorylation and up-regulation of Kv channels, and most likely accounted for reduced myelination observed *in vivo*.

From these findings we deduced that a normal role of cyt-PTP ϵ in Schwann cells was to lower tyrosine phosphorylation levels and activities of Kv channel alpha-subunits. This conclusion was strengthened by the ability of cyt-PTP ϵ to reduce Src-mediated phosphorylation of Kv2.1 *in vivo* (Figure 9). PTP ϵ could presumably act either directly, by dephosphorylating Kv channel proteins, or indirectly, by dephosphorylating and inactivating kinases (chiefly Src and Fyn), which phosphorylate and activate Kv channels (Peretz et al., 1999). Further studies revealed that activities and phosphorylation levels of Src and of Fyn were similar in Schwann cells of PTP ϵ -deficient and of wild-type mice (not shown), strongly suggesting that Src and Fyn were not major mediators of the effect of cyt-PTP ϵ on Kv channels. This raised the possibility that PTP ϵ directly dephosphorylated Kv channel alpha subunits.

Use of PTP ϵ substrate-trapping mutants: In order to determine whether Kv channel alpha subunits were in fact substrates of PTP ϵ , we made use of the D-to-A mutants of PTP ϵ described above. The purpose of this experiment was to determine whether the major Kv channel alpha-subunit found in Schwann cells, Kv2.1, would specifically bind the D-to-A mutant of PTP ϵ at the latter's active site. For this purpose, we transiently expressed Kv2.1 in 293 cells together with wild-type or the D-to-A mutant of PTP ϵ . PTP ϵ was immune-precipitated using anti-FLAG antibodies, and presence of associated Kv2.1 was examined by protein blotting with anti-Kv2.1 antibodies. As seen in Figure 10, low levels of Kv2.1 reproducibly precipitated with wild-type PTP ϵ . However, significantly more Kv2.1 co-precipitated with the D-to-A mutant of PTP ϵ , indicating that the D-to-A mutation had significantly increased the ability of PTP ϵ to bind Kv2.1. Furthermore, this increased binding was eliminated by the presence of sodium pervanadate in the precipitation reaction. This last finding is critical, as pervanadate oxidizes the cysteine residue located at the catalytic center of PTPases; in the

PAGE CONTAINS UNPUBLISHED DATA WHICH SHOULD BE PROTECTED

case of D-to-A mutants, this is known to prevent association between the active site of the mutant molecules and their putative substrates (Flint et al., 1997). Together, these experiments clearly demonstrate that the interaction between Kv2.1 and PTP ϵ is mediated by the active site of the phosphatase, a finding which is clearly consistent with Kv2.1 being a substrate of PTP ϵ .

In line with the above results, expression of wild-type PTP ϵ together with Kv2.1 in *Xenopus* oocytes severely reduced voltage-gated potassium currents caused by Kv2.1 (Figure 11). However, expression of the D-to-A mutant of PTP ϵ in similar experiments had little effect on Kv2.1 activity (Figure 11). This indicates that the D-to-A mutant PTP ϵ molecule is in fact catalytically inactive also as judged in a functional assay which is more specific and physiological than the PNPP dephosphorylation assay described above. Residual reduction in Kv2.1 activity caused by D-to-A PTP ϵ can be readily explained by mutant PTP ϵ binding to some Kv2.1 molecules and thus preventing them from functioning. This effect is expected to be much weaker than enzymatic dephosphorylation of Kv2.1 molecules by active PTP ϵ , as the latter effect is catalytic, while binding is a stoichiometric process in which each PTP ϵ molecule can affect only a single Kv2.1 molecule.

In all, studies performed during this past year have been useful and relevant for future use of D-to-A mutants of PTP ϵ in studies of breast cancer because:

- A. We have constructed D-to-A substrate-trapping mutants of PTP ϵ ; these mutants are key reagents, without which future work would have been impossible.
- B. We have had the opportunity to demonstrate that the D-to-A mutants of PTP ϵ actually function as expected both *in vitro* and *in vivo*, and are appropriate tools for performing the studies we have planned.
- C. We have had the opportunity to work out experimental difficulties associated with the techniques of immune-precipitation using substrate-trapping mutants, in a situation where we felt that we had a good candidate substrate at hand. The detailed technical aspects of the study, while not discussed in detail, are critical, as immune-precipitation experiments are typically quite tricky to perform.
- D. From the scientific-biological point of view, the results obtained are relevant for the original purpose set forth in the Proposal, as Kv channels are widely expressed and could conceivably be found also in mammary tumor cell lines. We intend to develop this issue further as explained below.
- E. These studies have provided us with an invaluable positive control for future studies in which we will attempt to identify previously-unknown substrates of PTP ϵ .
- F. This study has reaffirmed that examining whether candidate substrate molecules are in fact substrates of PTP ϵ is a worthy approach and, provided the "educated guesses" made are reasonable, can significantly speed up the rate at which progress is made.

Due to these considerations, we propose to amend the experimental details by which future work will proceed to include:

1. Examination of whether Kv2.1 or any other known Kv channel alpha subunits of a similar nature against which antibodies are available are co-expressed together with PTP ϵ in mammary tumor cell lines. If so, to determine whether these subunits bind D-to-A mutants of PTP ϵ .

PAGE CONTAINS UNPUBLISHED DATA WHICH SHOULD BE PROTECTED

2. To examine whether specific molecules are in fact substrates of PTP ϵ . A prominent candidate substrate of PTP ϵ is Neu, as tm-PTP ϵ is specifically expressed, is tyrosine-phosphorylated, and binds Grb2, in mammary tumors initiated by Neu or Ras (Elson and Leder, 1995a; Toledano-Katchalski and Elson, 1999; Gil-Henn et al., in preparation; Figure 12). Another potential substrate of PTP ϵ is c-Src, as Src is dephosphorylated and activated by PTP α , a PTPase extremely closely related to tm-PTP ϵ (Zheng et al., 1992; Su et al., 1999; Ponniah et al., 1999). Furthermore, Src is often activated in mammary tumors initiated by Neu (Muthuswamy et al., 1994; Muthuswamy and Muller, 1995a, 1995b). Initial steps in this direction will be to determine whether Src or Neu bind D-to-A mutants of PTP ϵ .

3. We intend to proceed also with the original plan of research, which includes search for unknown substrates of PTP ϵ in mammary tumor cell lines according to the procedures elaborated in the original Proposal.

7. Key Research Accomplishments:

- * Construction of GST fusion proteins of D-to-A substrate-trapping mutants.
- * Construction of D-to-A substrate-trapping mutants of tm-PTP ϵ and of cyt-PTP ϵ , in eukaryotic expression vector form.
- * Demonstration that these reagents behave as expected (catalytically inactive *in vitro* and *in vivo*; specifically bind Kv channels).
- * Demonstration that alpha-subunits of voltage-gated potassium (Kv) channels are substrates of PTP ϵ .

8. Reportable Outcomes:Manuscripts:

1. Peretz, A., Gil-Henn, H., Sobko, A., Attali, B and Elson, A. - Hypomyelination and increased activity of voltage-gated potassium channels in mice lacking protein tyrosine phosphatase ϵ . (*in preparation*).

Abstracts and presentations:

1. Concerted activities of protein tyrosine phosphatase epsilon and tyrosine kinases in regulating activity of voltage-gated potassium channels *in vivo*.
Ari Elson, Bernard Attali, Asher Peretz, Alex Sobko, and Hava Gil.
FASEB meeting on kinases and protein phosphorylation. Snowmass, Colorado, USA. July 24-29, 1999. (Poster).
2. Concerted activities of protein tyrosine phosphatase epsilon and tyrosine kinases in regulating activity of voltage-gated potassium channels *in vivo*.
Lecture presented (by Ari Elson) at the Department of Genetics, Harvard Medical School, Boston, USA, July 30, 1999.
3. Protein tyrosine phosphatase epsilon inactivates voltage-gated potassium channels *in vivo*.
Ari Elson, Bernard Attali, Asher Peretz, Hava Gil, and Alex Sobko.
EMBO-FEBS Workshop on Protein Phosphatases and Protein Dephosphorylation. September 19-24, 1999. De-Panne, Belgium. (Oral presentation).

PAGE CONTAINS UNPUBLISHED DATA WHICH SHOULD BE PROTECTEDPatents:

N/A (not applicable).

Degrees obtained due to support by this grant:

None (yet: grant is supporting work of individuals listed below, although they have not yet obtained their degrees).

Cell lines/repositories:

N/A

Informatics:

N/A

Funding applied for based on this work:

We have applied for a grant from the Israeli Academy of Sciences to pursue further the Kv-PTP ϵ paradigm established here in aspects which do not overlap with breast cancer studies as outlined above (chiefly in lymphocyte and neural function). Funding is sought at a level of \$40,000/yr for four years (if approved).

Employment and research opportunities supported by this grant:

Funds support work performed by two PhD students in the lab - Ms. Hila Toledano-Katchalski (who also receives a stipend funded from this grant), and Ms. Hava Gil-Henn. Limited salary support for Mr. Bernard Danovitch, a research technician who assists our lab work, is also provided by this grant.

9. Conclusions:

Studies performed during the period covered by this report have allowed us to construct eukaryotic expression vectors for exogenous expression in cells of substrate-trapping D-to-A mutants of PTP ϵ . We have also demonstrated that these mutant molecules are catalytically inactive, as expected from published literature which describes D-to-A mutants of PTPases. We have made use of these mutants in the closing phases of another research project, in which we were able to demonstrate that alpha subunits of voltage-gated potassium (Kv) channels are physiological substrates of cyt-PTP ϵ . This finding provided a much-needed mechanistic explanation for our previous finding that myelination is impaired in the sciatic nerves of young PTP ϵ -deficient mice, linking this finding with impaired phosphorylation of Kv channels due to lack of cyt-PTP ϵ . Substrate-trapping reagents developed here were important for that study as they enabled us to unequivocally demonstrate physical interaction between the catalytic site of cyt-PTP ϵ and Kv2.1, a prominent Kv channel alpha subunit present in Schwann cells.

Studies outlined here have allowed us to unequivocally demonstrate that our D-to-A substrate trapping mutants of PTP ϵ in fact function as they were expected and provided us with an important opportunity to calibrate our working procedures on what has now been established as a substrate of PTP ϵ . Furthermore, we now have in hand a positive control for future experiments, as well as a potential substrate for PTP ϵ also in the context of mammary tumor cells.

PAGE CONTAINS UNPUBLISHED DATA WHICH SHOULD BE PROTECTED

Based on the studies of the past year we recommend to include two additional topics in this study: determination of whether Kv channels are substrates of PTP ϵ also in mammary tumor cells, and determination of whether other specific candidate substrates of PTP ϵ , most prominently Neu and Src, are in fact substrates of the enzyme in mammary tumor cells.

From the scientific point of view, studies performed here have established a clear role for PTP ϵ *in vivo* in regulation of axon myelination in young mice and have established a paradigm which we hope will also extend to mammary tumors. We have established that alpha subunits of Kv channels are physiological substrates of cyt-PTP ϵ in Schwann cells, and that inappropriate dephosphorylation of these channels reduces their ability to function properly. These studies are the first to demonstrate a link between a specific PTPase and regulation of Kv function *in vivo*, and may ultimately link PTP ϵ function to diseases caused by aberrant myelination of axons.

10. References:

- Elson, A. and Leder, P. (1995a) - Protein tyrosine phosphatase Epsilon: an isoform specifically expressed in mammary tumors initiated by *v-Ha-ras* or *neu*. J. Biol. Chem. 270 (44), 26116-26122.
- Elson, A. and Leder, P. (1995b)- Identification of a cytoplasmic, phorbol ester-inducible isoform of the protein tyrosine phosphatase Epsilon. Proc. Natl. Acad. Sci. USA 92 (26), 12235-12239.
- Flint, A.J., Tiganis, T., Barford, D. and Tonks, N.K. (1997) - Development of "substrate-trapping" mutants to identify physiological substrates of protein tyrosine phosphatases. Proc. Natl. Acad. Sci. USA 94, 1680-1685.
- Huyer, G., Liu, S., Kelly, J., Moffat, J., Payette, P., Kennedy, B., Tsapralis, G., Gresser, M.J., and Ramachandran, C. (1997). Mechanism of inhibition of protein-tyrosine phosphatases by vanadate and pervanadate. J. Biol. Chem. 272, 843-851.
- Kunkel, T. A. (1985). Rapid and efficient site-specific mutagenesis without phenotypic selection. Proc. Natl. Acad. Sci. USA 82, 488-492.
- Lewis, R.S. and Cahalan, M.D. (1995). Potassium and calcium channels in lymphocytes. Annu. Rev. Immunol. 13, 623-653.
- Muthuswamy, S.K., Siegel, P.M., Dankort, D.L., Webster, M.A. and Muller, W.J. (1994). Mammary tumors expressing the neu proto-oncogene possess elevated c-Src tyrosine kinase activity. Mol. Cell. Biol. 14(1), 735-743.
- Muthuswamy, S.K. and Muller, W.J. (1995a). Direct and specific interaction of c-Src with Neu is involved in signaling by the epidermal growth factor receptor. Oncogene 11(2), 271-279.
- Muthuswamy, S.K. and Muller, W.J. (1995b). Activation of Src family kinases in Neu-induced mammary tumors correlates with their association with distinct sets of tyrosine phosphorylated proteins *in vivo*. Oncogene 11(9), 1801-1810.
- Peretz, A., Sobko, A. & Attali, B. (1999). Tyrosine kinases modulate K⁺ channel gating in mouse Schwann cells. J. Physiol (Lond) 519, 373-384.
- Ponniah, S., Wang, D.Z., Lim, K.L. & Pallen, C.J. (1999). Targeted disruption of the tyrosine phosphatase PTPalpha leads to constitutive downregulation of the kinases Src and Fyn. Curr. Biol. 9, 535-538.

- Su, J., Muranjan, M. & Sap, J. (1999) Receptor protein tyrosine phosphatase alpha activates Src-family kinases and controls integrin-mediated responses in fibroblasts. *Curr. Biol.* 9, 505-511.
- Sun, H., Charles, C.H., Lau, L.F. and Tonks, N.K. (1993) - MKP-1 (3CH134), an immediate early gene product, is a dual specificity phosphatase that dephosphorylates MAP kinase *in vivo*. *Cell* 75 (3), 487-493.
- Zheng, X.M., Wang, Y. and Pallen, C.J. (1992). Cell transformation and activation of pp60c-src by overexpression of a protein tyrosine phosphatase. *Nature* 359, 336-339.




Figure 1: Fragments of tm-PTPε cDNA amplified by PCR for generation of GST-PTPε fusion proteins. Precise sequences of oligonucleotides are given in the text. Black rectangles denote the catalytic domains of PTPε; asterisks denote locations of the aspartic acid mutated to an alanine in D-to-A mutant versions of these constructs.





Figure 2: Expression of GST-PTPε fusion proteins. GST fusion proteins of the membrane-proximal catalytic domain of PTPε (D1, construct #308) or of both catalytic domains (D1&D2, construct #304) were constructed as described in the text of the report. Fusion proteins were expressed in BL-21 bacteria and purified using glutathione-agarose beads. Crude bacterial extracts (C) or purified proteins (P) were electrophoresed through a 10% SDS-polyacrylamide gel and stained with Coomassie Brilliant Blue. Arrows denote location of bands of full length GST-PTPε fusion proteins in the lanes containing pure (P) fusion protein in the D1 or D1&D2 lanes. Numbers on the left indicate molecular size markers (in kDa).

A



B




Figure 3: A. Schematic diagram of tm-PTP ϵ and cyt-PTP ϵ cDNAs used in eukaryotic expression studies. Black rectangles denote catalytic domains, ellipses denote FLAG-tag appended to C-termini of some constructs. All cDNAs were cloned into the pCDNA3 expression plasmid. Asterisk marks spot where the D-to-A mutation was inserted. B. Protein blot documenting expression of cDNAs shown in panel A. Proteins were expressed in 293 cells, immune-precipitated using anti-FLAG antibodies, blotted, and probed with an anti-PTP ϵ antibody. Band marked with a single asterisk is unglycosylated tm-PTP ϵ (Elson and Leder, 1995a). Band marked with two asterisks represents a novel, truncated form of PTP ϵ (Gil-Henn et al, in preparation).




Figure 4: PTP ϵ catalytic activity of wild-type (WT) or D-to-A type mutants (MUT) of tm-PTP ϵ and cyt-PTP ϵ . 293 cells were transfected with the relevant expression vectors, and total PTPase activity, defined as pervanadate-sensitive para-nitrophenylphosphate dephosphorylating activity, was measured. Asterisk denotes FLAG-tagged PTP ϵ . Shown are results of one out of three experiments performed.




Figure 5: Expression of cyt-PTP ϵ in primary Schwann cells of PTP ϵ -Deficient (KO) or wild-type (WT) mice. Protein extracts of either cell type were electrophoresed and blotted using anti-PTP ϵ antibodies.




Figure 6: Reduced myelination of axons in sciatic nerves of 5-day old PTP ϵ -deficient (KO, solid) and wild-type (WT, stippled) mice. Cross-sections of sciatic nerve tissue were examined with an electron microscope. Mean sheath thicknesses were (in microns, $\pm$ SEM): KO: 0.23 ± 0.05 , $n=456$; WT: 0.37 ± 0.06 , $n=526$. $p < 0.0001$ by the Mann-Whitney test.




Figure 8: Kv channel activity is upregulated in primary Schwann cells from PTP ϵ -deficient mice. Whole-cell patch-clamp measurements of Kv channel currents induced in wild-type (WT) or PTP ϵ -deficient (KO) cells by successive depolarizations from -60mV to +80mV. Current induced in KO cells is significantly stronger than in WT cells for a given depolarization value. This set of studies was performed in collaboration with Dr. Bernard Attali, of the Department Of Neurobiology of The Weizmann Institute.




Figure 7: Hyperphosphorylation of Kv channel α -subunits in PTP ϵ -deficient sciatic nerve and primary Schwann cells. Kv2.1 or Kv1.5 were immune-precipitated; blots were probed with anti-phosphotyrosine or anti-Kv antibodies.




Figure 9: PTP ϵ reduces Src-mediated phosphorylation of Kv2.1. 293 cells were transiently transfected with the indicated expression vectors; tyrosine phosphorylation of Kv2.1 was estimated by immune-precipitating tyrosine-phosphorylated proteins, followed by blotting for Kv2.1 (top). Remaining panels document expression of Kv2.1, Src, or PTP ϵ as indicated.




Figure 10: Kv2.1 preferentially binds the D245A substrate-trapping mutant of cyt-PTP ϵ . 293 cells were transfected with WT cyt-PTP ϵ , D245A cyt-PTP ϵ , and Kv2.1 as indicated. Following precipitation of PTP ϵ (via its FLAG tag), precipitates were analyzed for presence of Kv2.1. Note that some Kv2.1 specifically binds wt cyt-PTP ϵ ; much more binds D245A cyt-PTP ϵ , and this added binding is removed by pervanadate.




Figure 11: cyt-PTP ϵ reduces Kv2.1-mediated potassium currents in *Xenopus* oocytes. Left: Kv channel currents induced by depolarization in *Xenopus* oocytes expressing Kv2.1. Kv currents are significantly inhibited by co-expression of active cyt-PTP ϵ (middle), but not of a D-to-A mutant of cyt-PTP ϵ (right). Bottom: same data in the form of a graph. Experiment was performed in collaboration with Dr. Bernard Attali.




Figure 12: Neu phosphorylates tm-PTP ϵ in Transfected cells. 293 cells were transfected with vectors encoding tm-PTP ϵ or Neu as indicated. Following immunoprecipitation of tm-PTP ϵ - via its FLAG-tag - blot was reacted with anti-phosphotyrosine antibodies. Lane marked with an asterisk shows migration of int-PTP ϵ and of partially-glycosylated tm-PTP ϵ (Elson and Leder, 1995a).



DEPARTMENT OF THE ARMY
US ARMY MEDICAL RESEARCH AND MATERIEL COMMAND
504 SCOTT STREET
FORT DETRICK, MARYLAND 21702-5012

REPLY TO
ATTENTION OF:

MCMR-RMI-S (70-1y)

26 Nov 02

MEMORANDUM FOR Administrator, Defense Technical Information
Center (DTIC-OCA), 8725 John J. Kingman Road, Fort Belvoir,
VA 22060-6218


SUBJECT: Request Change in Distribution Statement

1. The U.S. Army Medical Research and Materiel Command has reexamined the need for the limitation assigned to technical reports written for this Command. Request the limited distribution statement for the enclosed accession numbers be changed to "Approved for public release; distribution unlimited." These reports should be released to the National Technical Information Service.

2. Point of contact for this request is Ms. Kristin Morrow at DSN 343-7327 or by e-mail at Kristin.Morrow@det.amedd.army.mil.

FOR THE COMMANDER:

Encl



PHYLLIS M. RINEHART
Deputy Chief of Staff for
Information Management

ADB263708
ADB257291
ADB262612
ADB266082
ADB282187
ADB263424
ADB267958
ADB282194
ADB261109
ADB274630
ADB244697
ADB282244
ADB265964
ADB248605
ADB278762
ADB264450
ADB279621
ADB261475
ADB279568
ADB262568
ADB266387
ADB279633
ADB266646
ADB258871
ADB266038
ADB258945
ADB278624